SUPN - Supernus Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Rockville,
United States
Type: Equity
SUPN price evolution
SUPN
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $52.09 | $63.4 | $75.05 | |
| Short term investments | $295.1 | $234.34 | $179.82 | |
| Net receivables | $145.41 | $152.49 | $147.73 | $144.16 |
| Inventory | $63.98 | $68.16 | $75.08 | $77.41 |
| Total current assets | $640 | $591 | $544.32 | $493.11 |
| Long term investments | $11.66 | $16.62 | ||
| Property, plant & equipment | $37.96 | $12.27 | $12.97 | $13.53 |
| Goodwill & intangible assets | $676.66 | $696.77 | $716.91 | |
| Total noncurrent assets | $724.83 | $759.77 | $784.56 | |
| Total investments | $295.1 | $246 | $196.44 | |
| Total assets | $1342.7 | $1315.83 | $1304.09 | $1277.67 |
| Current liabilities | ||||
| Accounts payable | $6.39 | $82.61 | $86.4 | $79.57 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $291.51 | $308.66 | $314.55 | $290.2 |
| Long term debt | $30.29 | $32.99 | $33.2 | |
| Total noncurrent liabilities | $49.72 | $60.37 | $65.96 | |
| Total debt | $30.29 | $32.99 | $33.2 | |
| Total liabilities | $335.55 | $358.38 | $374.92 | $356.16 |
| Shareholders' equity | ||||
| Retained earnings | $541.1 | $502.6 | $482.69 | $482.56 |
| Other shareholder equity | $0.08 | -$0.37 | -$0.53 | -$0.59 |
| Total shareholder equity | $957.45 | $929.17 | $921.52 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $75.05 | $93.12 | $203.43 | $288.64 |
| Short term investments | $179.82 | $368.21 | $136.25 | $133.89 |
| Net receivables | $144.16 | $165.5 | $148.93 | $140.9 |
| Inventory | $77.41 | $91.54 | $85.96 | $48.3 |
| Total current assets | $493.11 | $734.15 | $601.59 | $630.4 |
| Long term investments | $16.62 | $93.9 | $119.17 | $350.36 |
| Property, plant & equipment | $13.53 | $44.08 | $52.32 | $58.1 |
| Goodwill & intangible assets | $716.91 | $819.48 | $902.21 | $442.25 |
| Total noncurrent assets | $784.56 | $968.36 | $1087.56 | $873.68 |
| Total investments | $196.44 | $462.11 | $255.41 | $484.25 |
| Total assets | $1277.67 | $1702.51 | $1689.15 | $1504.1 |
| Current liabilities | ||||
| Accounts payable | $79.57 | $10.54 | $9.33 | $6.1 |
| Deferred revenue | ||||
| Short long term debt | $401.97 | |||
| Total current liabilities | $290.2 | $687.96 | $315.38 | $245.1 |
| Long term debt | $33.2 | $36 | $379.25 | $382 |
| Total noncurrent liabilities | $65.96 | $128.35 | $557.92 | $514.14 |
| Total debt | $33.2 | $437.97 | $420.55 | $390.33 |
| Total liabilities | $356.16 | $816.3 | $873.3 | $759.2 |
| Shareholders' equity | ||||
| Retained earnings | $482.56 | $481.25 | $379.92 | $326.5 |
| Other shareholder equity | -$0.59 | -$3.21 | $1.54 | $9 |
| Total shareholder equity | $921.52 | $886.2 | $815.85 | $744.86 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $175.69 | $168.32 | $143.64 | $164.31 |
| Cost of revenue | $17.92 | $16.31 | $19.63 | |
| Gross Profit | $158.11 | $150.41 | $127.33 | $144.69 |
| Operating activities | ||||
| Research & development | $26.18 | $24.93 | $23.35 | |
| Selling, general & administrative | $85.9 | $86.52 | $81.28 | |
| Total operating expenses | $117.26 | $127.84 | $131.58 | $147.2 |
| Operating income | $22.57 | -$4.25 | -$2.51 | |
| Income from continuing operations | ||||
| EBIT | $26.3 | $0.24 | $0.99 | |
| Income tax expense | $6.45 | $6.39 | $0.12 | -$0.18 |
| Interest expense | $4.1 | |||
| Net income | ||||
| Net income | $38.5 | $19.92 | $0.12 | $1.18 |
| Income (for common shares) | $19.92 | $0.12 | $1.18 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $607.52 | $667.24 | $579.77 | $520.4 |
| Cost of revenue | $83.78 | $87.22 | $75.06 | $52.46 |
| Gross Profit | $523.74 | $580.02 | $504.71 | $467.94 |
| Operating activities | ||||
| Research & development | $91.59 | $74.55 | $90.47 | $75.96 |
| Selling, general & administrative | $336.36 | $377.22 | $304.76 | $200.68 |
| Total operating expenses | $530.53 | $533.89 | $418.69 | $294.24 |
| Operating income | -$6.79 | $46.12 | $86.03 | $173.7 |
| Income from continuing operations | ||||
| EBIT | $5.18 | $67.81 | $96.6 | $192.4 |
| Income tax expense | $1.45 | $0.03 | $19.75 | $41.7 |
| Interest expense | $2.42 | $7.07 | $23.42 | $23.75 |
| Net income | ||||
| Net income | $1.32 | $60.71 | $53.42 | $126.95 |
| Income (for common shares) | $1.32 | $60.71 | $53.42 | $126.95 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $19.92 | $0.12 | $1.18 | |
| Operating activities | ||||
| Depreciation | $20.72 | $20.75 | $21.68 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.55 | $5.9 | $6.45 | |
| Total cash flows from operations | $35.62 | $38.4 | $44.96 | |
| Investing activities | ||||
| Capital expenditures | -$0.06 | -$0.25 | $0.04 | |
| Investments | -$48.53 | -$51.38 | -$66.02 | |
| Total cash flows from investing | -$177.23 | -$48.59 | -$51.62 | -$65.98 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.66 | $2.91 | $3.08 | |
| Net borrowings | ||||
| Total cash flows from financing | $6.3 | $1.66 | $1.57 | $1.09 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$43.38 | -$11.31 | -$11.65 | -$19.93 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $1.32 | $60.71 | $53.42 | $126.95 |
| Operating activities | ||||
| Depreciation | $84.86 | $85.54 | $32.59 | $18.14 |
| Business acquisitions & disposals | -$298.8 | -$313.54 | ||
| Stock-based compensation | $26.76 | $17.57 | $17.91 | $16.56 |
| Total cash flows from operations | $111.08 | $116.83 | $127.13 | $138.4 |
| Investing activities | ||||
| Capital expenditures | -$0.55 | -$0.41 | -$2.04 | -$3.45 |
| Investments | $269.28 | -$216.25 | $218.94 | $282.53 |
| Total cash flows from investing | $268.73 | -$216.66 | -$81.91 | -$34.7 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.61 | $12.42 | $7.09 | $4.36 |
| Net borrowings | -$402.5 | -$137.51 | -$0.8 | |
| Total cash flows from financing | -$397.88 | -$10.48 | -$130.42 | $3.56 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$18.07 | -$110.31 | -$85.21 | $107.26 |
News
Fundamentals
| Market cap | $1.81B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 55.22M |
| Revenue | $651.97M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $59.71M |
| Revenue Q/Q | 14.17% |
| Revenue Y/Y | 6.79% |
| P/E ratio | 30.28 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 2.77 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $1.08 |
|---|---|
| ROA | 4.56% |
| ROE | N/A |
| Debt/Equity | 0.39 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.20 |
| Quick ratio | 1.98 |